EA038090B1 - Ингибиторы magl - Google Patents

Ингибиторы magl Download PDF

Info

Publication number
EA038090B1
EA038090B1 EA201991073A EA201991073A EA038090B1 EA 038090 B1 EA038090 B1 EA 038090B1 EA 201991073 A EA201991073 A EA 201991073A EA 201991073 A EA201991073 A EA 201991073A EA 038090 B1 EA038090 B1 EA 038090B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutically acceptable
compound
formula
acceptable salt
solvate
Prior art date
Application number
EA201991073A
Other languages
English (en)
Russian (ru)
Other versions
EA201991073A1 (ru
Inventor
Шерил А. Грайс
Дэниел Дж. Бузард
Майкл Б. Шагхафи
Original Assignee
Абайд Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Абайд Терапьютикс, Инк. filed Critical Абайд Терапьютикс, Инк.
Publication of EA201991073A1 publication Critical patent/EA201991073A1/ru
Publication of EA038090B1 publication Critical patent/EA038090B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/195Radicals derived from nitrogen analogues of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205Radicals derived from carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201991073A 2016-11-16 2017-11-15 Ингибиторы magl EA038090B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662423099P 2016-11-16 2016-11-16
PCT/US2017/061868 WO2018093947A1 (en) 2016-11-16 2017-11-15 Magl inhibitors

Publications (2)

Publication Number Publication Date
EA201991073A1 EA201991073A1 (ru) 2019-12-30
EA038090B1 true EA038090B1 (ru) 2021-07-05

Family

ID=62106678

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991073A EA038090B1 (ru) 2016-11-16 2017-11-15 Ингибиторы magl

Country Status (29)

Country Link
US (1) US10093635B2 (enExample)
EP (1) EP3541821A4 (enExample)
JP (1) JP7042547B2 (enExample)
KR (1) KR20190077544A (enExample)
CN (1) CN110267963B (enExample)
AR (1) AR110089A1 (enExample)
AU (1) AU2017361251B2 (enExample)
BR (1) BR112019009994A2 (enExample)
CA (1) CA3043615A1 (enExample)
CL (1) CL2019001339A1 (enExample)
CO (1) CO2019005059A2 (enExample)
CR (1) CR20190241A (enExample)
DO (1) DOP2019000122A (enExample)
EA (1) EA038090B1 (enExample)
EC (1) ECSP19035077A (enExample)
GE (1) GEP20237470B (enExample)
IL (1) IL266523B (enExample)
JO (1) JOP20190106A1 (enExample)
MA (1) MA46857A (enExample)
MX (1) MX391117B (enExample)
NI (1) NI201900051A (enExample)
PE (1) PE20191144A1 (enExample)
PH (1) PH12019501097A1 (enExample)
RU (1) RU2754536C1 (enExample)
TN (1) TN2019000153A1 (enExample)
TW (1) TWI756299B (enExample)
UA (1) UA124542C2 (enExample)
WO (1) WO2018093947A1 (enExample)
ZA (1) ZA201903100B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350788B (es) 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
WO2018053447A1 (en) 2016-09-19 2018-03-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
WO2018093950A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
AU2017361257B2 (en) 2016-11-16 2022-02-10 H. Lundbeck A/S. Crystalline forms of a MAGL inhibitor
LT3630744T (lt) 2017-05-23 2023-03-10 H. Lundbeck A/S Pirazolo magl inhibitoriai
MX2020002251A (es) 2017-08-29 2020-07-20 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso.
CN112088001A (zh) 2018-05-15 2020-12-15 隆德贝克拉荷亚研究中心有限公司 Magl抑制剂
EP3914589A4 (en) * 2019-01-25 2022-11-30 H. Lundbeck A/S Methods of treating disease with magl inhibitors
CA3159391A1 (en) * 2019-11-15 2021-05-20 H. Lundbeck A/S Crystalline forms of a magl inhibitor
IT202000007150A1 (it) * 2020-04-03 2021-10-03 Univ Pisa Inibitori di monoacilglicerolo lipasi (magl)
IL297470A (en) 2020-04-21 2022-12-01 H Lundbeck As Synthesis of a monoacylglycerol lipase inhibitor
US20250084065A1 (en) 2021-12-29 2025-03-13 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
US12378219B2 (en) 2022-05-04 2025-08-05 H. Lundbeck A/S Crystalline forms of a MAGL inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150148330A1 (en) * 2012-01-06 2015-05-28 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
WO2016014975A2 (en) * 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
US20160137649A1 (en) * 2013-07-03 2016-05-19 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016149401A2 (en) * 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (enExample) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
ATE138365T1 (de) 1991-11-27 1996-06-15 Du Pont Herbizide acylierte amino-(phenyl-oder-pyridinyl- oder thienyl-)phenyl derivate
AU1384795A (en) 1993-12-22 1995-07-10 Shell Internationale Research Maatschappij B.V. Process for preparing carbamates
EP0863879A1 (en) 1995-11-15 1998-09-16 Zeneca Limited Herbicidal substituted pyrazole compounds
WO1998000408A1 (en) 1996-07-02 1998-01-08 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
EP1226115A4 (en) 1999-10-04 2006-03-15 Univ New Jersey Med NEW CARBAMATES AND UREES
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
AU2003300702A1 (en) 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Process for preparing carbamates
EP1716130A1 (en) 2004-02-18 2006-11-02 AstraZeneca AB Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
JP2008521768A (ja) 2004-12-23 2008-06-26 エフ.ホフマン−ラ ロシュ アーゲー ヘテロ環式カルバミン酸誘導体、それらの製造及び医薬品としての使用
EP2937341B1 (en) 2004-12-30 2017-07-05 Janssen Pharmaceutica N.V. 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions
JP2009514935A (ja) * 2005-11-05 2009-04-09 アストラゼネカ・アクチエボラーグ 新規化合物
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス,インコーポレーテッド C型肝炎の治療方法
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
EP2124927A2 (en) 2007-02-26 2009-12-02 Kosan Biosciences Incorporated Carbamate compounds
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
AU2009270983A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and their use as GPCR modulators
AU2009314629B2 (en) 2008-11-14 2014-09-25 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
JP2012521425A (ja) 2009-03-23 2012-09-13 Msd株式会社 オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
EP2421848A1 (en) * 2009-04-22 2012-02-29 Janssen Pharmaceutica N.V. Azetidinyl diamides as monoacylglycerol lipase inhibitors
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
TWI506011B (zh) 2009-11-03 2015-11-01 Bayer Materialscience Ag 在光聚合物調配物中作為添加劑之氟胺基甲酸酯
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
CA2860623A1 (en) 2012-01-06 2013-07-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
JP6100883B2 (ja) 2012-03-19 2017-03-22 アビデ セラピューティクス,インク. カルバマート化合物、及びその製造並びに使用
JP2014005245A (ja) * 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
WO2018053447A1 (en) * 2016-09-19 2018-03-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150148330A1 (en) * 2012-01-06 2015-05-28 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
US20160137649A1 (en) * 2013-07-03 2016-05-19 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016014975A2 (en) * 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
WO2016149401A2 (en) * 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same

Also Published As

Publication number Publication date
TN2019000153A1 (en) 2020-10-05
UA124542C2 (uk) 2021-10-05
US20180134674A1 (en) 2018-05-17
AU2017361251A1 (en) 2019-05-30
GEP20237470B (en) 2023-02-10
JP2020504707A (ja) 2020-02-13
US10093635B2 (en) 2018-10-09
KR20190077544A (ko) 2019-07-03
BR112019009994A2 (pt) 2019-08-27
CL2019001339A1 (es) 2019-10-04
DOP2019000122A (es) 2019-09-30
IL266523B (en) 2022-09-01
EA201991073A1 (ru) 2019-12-30
AU2017361251B2 (en) 2021-08-19
TW201823216A (zh) 2018-07-01
RU2754536C1 (ru) 2021-09-03
ECSP19035077A (es) 2019-05-31
NZ753264A (en) 2020-12-18
MA46857A (fr) 2019-09-25
CR20190241A (es) 2019-09-02
EP3541821A4 (en) 2020-04-22
PH12019501097A1 (en) 2019-08-19
WO2018093947A1 (en) 2018-05-24
MX391117B (es) 2025-03-21
JP7042547B2 (ja) 2022-03-28
NI201900051A (es) 2019-10-30
MX2019005776A (es) 2019-12-05
AR110089A1 (es) 2019-02-20
ZA201903100B (en) 2020-11-25
CN110267963B (zh) 2022-04-01
PE20191144A1 (es) 2019-09-02
CN110267963A (zh) 2019-09-20
CA3043615A1 (en) 2018-05-24
TWI756299B (zh) 2022-03-01
JOP20190106A1 (ar) 2019-05-09
EP3541821A1 (en) 2019-09-25
CO2019005059A2 (es) 2019-05-31
IL266523A (en) 2019-07-31
RU2019116512A (ru) 2020-12-17

Similar Documents

Publication Publication Date Title
EA038090B1 (ru) Ингибиторы magl
AU2017361253B2 (en) MAGL inhibitors
ES2908632T3 (es) Inhibidores de MAGL
AU2019271123A1 (en) MAGL inhibitors
WO2017087858A1 (en) Pyrazole compounds and methods of making and using same
EP3515897A1 (en) Piperazine carbamates and methods of making and using same
AU2018236161A1 (en) Dual MAGL and FAAH inhibitors
WO2017059135A1 (en) Lp-pla2 inhibitors
NZ753264B2 (en) Magl inhibitors
HK40009163A (en) Magl inhibitors
HK40009163B (en) Magl inhibitors
HK40009161B (en) Magl inhibitors
HK40009161A (en) Magl inhibitors